Idiopathic pulmonary fibrosis (IPF) is a disease with both genetic variants and environmental risk factors leading to its development. The researchers at the University of Colorado have been studying this complex and rare disease for over 20 years. They’ve found insights into which genetics variants are most likely contributing to this disease as well as other factors that are linked to its development.

A new study was recently launched by this team titled “Advancing Prevention of Pulmonary Fibrosis (APPLe)”. As we continue to learn about genetic and environmental risk factors in the development of pulmonary fibrosis, learning from the early stages of this disease has become vital. Increasing our understanding of the early signs of this disease will help physicians across the world to diagnose their patients earlier and get those patients the necessary treatment they need at an earlier stage. This research study is for those who are most at risk for developing this disease. The inclusion criteria include having a first degree relative with IPF, having at least two members of your family being diagnosed with IPF, having no diagnosis of IPF yourself, and being between the age of 40-75. If this research study interests you, please reach out to the clinical team at the University of Colorado to learn more about how you can join.

Sincerely,

Dr. David Schwartz, Dr. Joyce Lee and the rest of the APPLe investigators

Rachel Warren, CCRP
Clinical Research Program Manager
University of Colorado | Division of Pulmonary Sciences
303-724-8569
Rachel.warren@cuanschutz.edu

COMIRB No: 20-1739: Cohort Study of Preclinical Pulmonary Fibrosis
Principal Investigator: David Schwartz, MD
Document Version Date: July 14, 2023